Back to dashboard
MedicaidPrior AuthMedium impact

Unloxcyt™ (cosibelimab-ipdl) (New)

Humana·OH · Oncology, Hematology·Medicaid
Effective date
Not stated
We identified it
Jun 24, 2026
Days to comply

Summary

A new prior authorization policy has been implemented for Unloxcyt™ (cosibelimab-ipdl), a specialty medication, specifically for Ohio Medicaid members. This drug requires prior approval before administration or dispensing.

Action Required

Action needed
Immediately: Billing team and providers must verify prior authorization approval before administering or dispensing Unloxcyt™ (cosibelimab-ipdl) to Ohio Medicaid patients. Update billing system to flag this medication for prior auth requirements. Claims submitted without prior authorization will be denied.